Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "Epilepsy Therapeutic Market in APAC 2024-2028" report has been added to ResearchAndMarkets.com's offering.
The epilepsy therapeutic market in the Asia Pacific region is witnessing significant growth, driven by the increasing need for effective treatment modalities and rising awareness about the neurological disorder. With an acceleration in compound annual growth rate (CAGR) of 4.19% expected over the next five years, the market is on track to expand by a substantial USD 449.35 million during the forecast period of 2023-2028.
Dynamics Fueling Market Expansion
This surge is attributed to a combination of factors, including the high unmet need for disease-modifying treatments and an increasing patient population diagnosed with epilepsy. Furthermore, initiatives to elevate the awareness level regarding epilepsy and its implications are contributing significantly to the market's growth trajectory.
Segmentation Insights
The market analysis segments the APAC epilepsy therapeutics into various distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies, to give a comprehensive understanding of the landscape. Additionally, the products are categorized into three generations of epilepsy therapeutics:
- First-generation epilepsy therapeutics
- Second-generation epilepsy therapeutics
- Third-generation epilepsy therapeutics
Innovations and Vendor Strategies
A key finding of the analysis is the ongoing reformulation of marketed epilepsy drugs, which stands as a crucial factor in amplifying the market's capacity. The advent of new-generation antiepileptic drugs (AEDs) with novel mechanisms of action is anticipated to foster sustained demand. The report strategically examines the positions of leading vendors in the APAC epilepsy therapeutic market to assist stakeholders in sharpening their competitive edge. While the report refrains from naming specific vendors, it offers a meticulous assessment of the market players, emphasizing the importance of their role in this evolving market landscape.
Market Analysis and Forecasting
This wide-ranging report takes into account the current market scenario, alongside emerging trends and drivers that are poised to shape the future of epilepsy therapeutics in the region. The insightful industry analysis is augmented by a compilation of key parameters such as profitability, competitive pricing strategies, and promotional activities.
Overarching Market Insights
The study combines valuable primary and secondary research, incorporating perspectives from key industry participants to provide a well-rounded view of the market. The wealth of data presented is derived from rigorous and trustworthy research methodologies. The summation of data from diverse sources results in a holistic market landscape, affording readers actionable insights and a thorough understanding of market influencers.
This resourceful report offers a definitive competitive landscape and an exhaustive selection methodology for vendors within the epilepsy therapeutic market in APAC. Fostering market growth, the report's forecasts and analyses equip companies with the strategic knowledge required to capitalize on upcoming opportunities within the Asia Pacific region for epilepsy therapeutics.
A selection of companies mentioned in this report includes
- Alkem Laboratories Ltd.
- Bausch Health Companies Inc.
- BIAL
- Dr Reddys Laboratories Ltd.
- Eisai Co. Ltd.
- H Lundbeck AS
- Johnson and Johnson
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- SK Inc.
- Sumitomo Pharma Co. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- UCB SA
- GlaxoSmithKline Plc
For more information about this report visit https://www.researchandmarkets.com/r/99ulcj
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
